Reanalysis of the ESPS 2 trial – Efficacy among high-risk subgroups
Results
Compared with ASA alone, extended-release dipyridamole plus ASA demonstrated a more pronounced efficacy in reducing the risk for stroke and vascular events among:
- patients younger than 70 years;
- those with hypertension,
- prior stroke, or
- transient ischaemic attack;
- current smokers;
- and those with any prior cardiovascular disease.
Relative hazard reductions favoured the combination of extended-release dipyridamole plus ASA, and were greatest for the high-risk Framingham Study group and the moderate-risk Stroke Prognostic Instrument II subgroup.
Conclusions
Extended-release dipyridamole plus ASA is more effective than ASA alone at preventing stroke, and the difference in efficacy increases in higher-risk patients.
References
Sacco et al. Arch Neurol 2005; 62 (3): 403-408.
PubMed Abstract
